Connect your AI

Absci Corporation ABSI AFS Securities

AFS Securities at other companies

ZymeworksZYME

$159.47M-35.0%

PrecigenPGEN

$489K-34.8%

Nektar TherapeuticsNKTR

$162.99M+7,973%

Arcus BiosciencesRCUS

$54M+575%

Other financials

Income statement

Revenue$215.0K-81.8%

Operating income-$30.8M-11.2%

Net income-$29.6M-12.3%

EPS (diluted)-$0.19+9.5%

Balance sheet

Cash & equivalents$9.7M-84.9%

Total debt$4.0M-37.2%

Total equity$172.0M-13.5%

Total assets$195.6M-15.9%

Cash flow

Operating cash flow-$26.3M-20.5%

CapEx$30.0K+20.0%

Free cash flow-$26.3M-20.5%

Valuation

Market cap$1.57B+341%

Enterprise value$1.57B+425%

P/S855.5×+782×

Profitability

Operating margin-6,723%-14,525pp

Net margin-6,450.8%-13,699pp

FCF margin-5,365.2%-9,300pp

Returns & leverage

Return on equity-63.9%+28.0pp

Debt / equity0×0.0×

Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Absci Corporation's AFS securities?: Absci Corporation (ABSI) reported AFS securities of $122.76M in Q1 2026.
How has Absci Corporation's AFS securities changed year-over-year?: Absci Corporation's AFS securities increased by 41.1% year-over-year, from $86.99M to $122.76M.
What is the long-term trend for Absci Corporation's AFS securities?: Over 3 years (2022 to 2025), Absci Corporation's AFS securities has grown at a 8.2% compound annual growth rate (CAGR), from $109.53M to $138.68M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.